Phathom Pharmaceuticals (PHAT) Earnings Yield: History & Chart

Phathom Pharmaceuticals, Inc.(PHAT)

Biotechnology · Florham Park, NJ

$6.59-0.11 (-1.64%)

Delayed quote: Oct 6, 2026, 2:00 PM EDT

About Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.

Florham Park, NJ

371 employees

www.phathompharma.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Steven L. Basta

View full financials

NAME	MARKET CAP	EARNINGS YIELD	TTM	3Y	5Y
Phathom Pharmaceuticals, Inc. (PHAT)	$533.14M	N/A	N/A	N/A	N/A
Nuvectis Pharma, Inc. (NVCT)vs ›	$533.91M	N/A	N/A	N/A	N/A
ProKidney Corp. (PROK)vs ›	$534.64M	N/A	N/A	N/A	N/A
Delcath Systems, Inc. (DCTH)vs ›	$534.91M	0.08%	0.28%	0.28%	0.28%
BlossomHill Therapeutics, Inc. (BLSM)vs ›	$531.17M	N/A	N/A	N/A	N/A
Aclaris Therapeutics, Inc. (ACRS)vs ›	$530.02M	N/A	N/A	N/A	N/A
Monopar Therapeutics Inc. (MNPR)vs ›	$538.60M	N/A	N/A	N/A	N/A
Shattuck Labs, Inc. (STTK)vs ›	$538.62M	N/A	N/A	N/A	N/A
Immix Biopharma, Inc. (IMMX)vs ›	$520.57M	N/A	N/A	N/A	N/A
Altimmune, Inc. (ALT)vs ›	$515.47M	N/A	516.44%	516.44%	516.44%

NAME

MARKET CAP

EARNINGS YIELD

TTM

Phathom Pharmaceuticals, Inc. (PHAT)

$533.14M

N/A

Nuvectis Pharma, Inc. (NVCT)vs ›

$533.91M

N/A

ProKidney Corp. (PROK)vs ›

$534.64M